India, Oct. 27 -- Clearmind Medicine Inc. (CMND) announced completion of patient recruitment for the first cohort of Part B of its Phase I/IIa clinical trial evaluating CMND-100 in patients with moderate-to-severe alcohol use disorder (AUD).
Part B marks the first clinical evaluation of CMND-100 in patients diagnosed with AUD, following completion of Part A in healthy volunteers.
The trial is designed to assess the treatment's safety, tolerability, pharmacokinetics, and early signs of clinical efficacy, including potential reductions in alcohol craving.
Part B includes two sequential single-dose ascending cohorts of 80 mg and 160 mg, with six patients in each cohort. The study is being conducted at clinical sites in the U.S. and Israel, ...